Abstract
Due to individual variations in radiosensitivity, biomarkers are needed to tailor radiation treatment to cancer patients. Since single nucleotide polymorphisms (SNPs) are frequent in human, we hypothesized that SNPs in genes that mitigate the radiation response are associated with radiotoxicity, in particular late complications to radiotherapy and could be used as genetic biomarkers for radiation sensitivity. A total of 155 patients with nasopharyngeal cancer were included in the study. Normal tissue fibrosis was scored using RTOG/EORTC grading system. Eleven candidate genes (
ATM
,
XRCC1
,
XRCC3
,
XRCC4
,
XRCC5
,
PRKDC
,
LIG4
,
TP53
,
HDM2
,
CDKN1A
,
TGFB1
) were selected for their presumed influence on radiosensitivity. Forty-five SNPs (12 primary and 33 neighboring) were genotyped by direct sequencing of genomic DNA. Patients with severe fibrosis (cases, G3–4,
n
= 48) were compared to controls (G0–2,
n
= 107). Results showed statistically significant (
P
< 0.05) association with radiation complications for six SNPs (
ATM
G/A rs1801516,
HDM2
promoter T/G rs2279744 and T/A rs1196333,
XRCC1
G/A rs25487,
XRCC5
T/C rs1051677 and
TGFB1
C/T rs1800469). We conclude that these six SNPs are candidate genetic biomarkers for radiosensitivity in our patients that have cumulative effects as patients with severe fibrosis harbored significantly higher number of risk alleles than the controls (
P
< 0.001). Larger cohort, independent replication of these findings and genome-wide association studies are required to confirm these results in order for SNPs to be used as biomarkers to individualize radiotherapy on genetic basis.